Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera.

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

Marcela Mazo Canola, MD, discusses pivotal trials in early-stage and metastatic HER2-positive breast cancer, plus ongoing trials to watch.

Ruben A. Mesa, MD, discusses the different disparities that are known to affect cancer care and key efforts being made to address them.

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Dr. Kaklamani discusses current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.

Sherri Cervantez, MD, discusses the utility of osimertinib in non–small cell lung cancer, as well as remaining questions regarding the treatment of patients who develop resistance to the third-generation EGFR inhibitor.

Dr. Mesa and Dr. Gerds provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.